FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)
As of Mon, 16 Nov 2026 05:48:14 UTC, Kalshi traders price Yes (89.0%). The market has $4K in volume and closes on Fri, 01 Jan 2027.
Updated:
Current odds
| Outcome | Chance | Yes price | No price |
|---|---|---|---|
| Yes | 89.0% | 89.0¢ | 11.0¢ |
Market details
- Venue: Kalshi
- Volume: $4K
- Liquidity: $4K
- Closes:
Resolution rules
If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Anitocabtagene autoleucel (anito-cel) is a personalized, one-time cell therapy made from a patient's own immune cells, reprogrammed in a laboratory to hunt and destroy cancer cells — think of it as taking a soldier from the patient's own army, giving it a custom-made targeting scope, and sending it back in. It is classified as a CAR-T (chimeric antigen receptor T-cell) therapy developed by Arcellx and commercialized in partnership with Gilead Sciences, designed to treat a blood cancer called multiple myeloma. In the trials studied here, it showed very high response rates, with nearly all treated patients responding to the therapy.
Sources
Related markets
- Who will be the next CEO of NVIDIA?
- S&P close price end of 2026?
- Nasdaq-100 close price end of 2026?
- Which brands will advertise during the World Soccer Cup Final
- Will GameStop acquire eBay this year?
- When will Apple release the iPhone 18?
More markets like this
- FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)
- FDA decision: Oveporexton by Takeda (this year)
- FDA decision: Saroglitazar by Zydus Therapeutics (this year)
- When will Beam Therapeutics submit a BLA for Risto-cel?
- Fed decision in December?
- Fed decisions (Oct-Jan)
- Fed decisions (Sep–Dec)
- Fed decisions December 2026 to March 2027?
A price on DOXA is the market-implied probability of an outcome on the venue that lists it. It is what traders are paying, not a forecast made by DOXA, and it is not investment advice. How DOXA shows prices · Terms of Use
DOXA is a liquidity aggregator for prediction markets that compares odds and depth across Polymarket, Kalshi and others and routes each trade for best execution with an AI assistant.